Title: Connecting the Missing Link Between Dilated Cardiomyopathy and Viral Myocarditis
Abstract: HomeCirculationVol. 115, No. 1Connecting the Missing Link Between Dilated Cardiomyopathy and Viral Myocarditis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBConnecting the Missing Link Between Dilated Cardiomyopathy and Viral MyocarditisVirus, Cytoskeleton, and Innate Immunity Yuichiro Maekawa, MD, PhD, Maral Ouzounian, MD, M. Anne Opavsky, MD, PhD and Peter P. Liu, MD Yuichiro MaekawaYuichiro Maekawa From the Heart and Stroke/Richard Lewar Centre of Excellence, and Toronto General Research Institute, University Health Network, Toronto, Canada (Y.M., M.O., P.P.L.); the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada (M.A.O.); and the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, Toronto and Ottawa, Canada (P.P.L.). , Maral OuzounianMaral Ouzounian From the Heart and Stroke/Richard Lewar Centre of Excellence, and Toronto General Research Institute, University Health Network, Toronto, Canada (Y.M., M.O., P.P.L.); the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada (M.A.O.); and the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, Toronto and Ottawa, Canada (P.P.L.). , M. Anne OpavskyM. Anne Opavsky From the Heart and Stroke/Richard Lewar Centre of Excellence, and Toronto General Research Institute, University Health Network, Toronto, Canada (Y.M., M.O., P.P.L.); the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada (M.A.O.); and the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, Toronto and Ottawa, Canada (P.P.L.). and Peter P. LiuPeter P. Liu From the Heart and Stroke/Richard Lewar Centre of Excellence, and Toronto General Research Institute, University Health Network, Toronto, Canada (Y.M., M.O., P.P.L.); the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada (M.A.O.); and the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, Toronto and Ottawa, Canada (P.P.L.). Originally published2 Jan 2007https://doi.org/10.1161/CIRCULATIONAHA.106.670554Circulation. 2007;115:5–8Myocarditis classically refers to inflammation of the heart muscle. The mechanisms include host immune dysregulation and viral triggers such as coxsackievirus (CVB), adenovirus, parvovirus, and hepatitis C virus. The pathophysiology is initiated by viral proliferation in a susceptible host, inducing host immune response. The latter, when exuberant, leads to myocyte destruction and dilated cardiomyopathy.1,2 Clinically, patients with viral myocarditis will spontaneously recover in one third of cases, persist with the disease in one third, and deteriorate in another third of the cases.Article p 94Recent biopsy series in patients with dilated cardiomyopathy have revealed an interesting situation in which patients with symptoms of heart failure may show the presence of the viral genome alone, without any evidence of an overt inflammatory process.3 This raises the question of whether the virus can be directly responsible for the cardiomyopathy or whether it is merely an incidental bystander.Viruses are exquisitely designed nanoparticles packaged with just the critical amount of genetic material to allow them to adapt to changing host and environmental conditions and to pass on genetic material to progeny. CVBs are single-stranded RNA viruses that have natural tropism for gut epithelial cells, immune cells, neurons, and cardiomyocytes. All strains of CVBs use the coxsackie–adenoviral receptor protein to gain entry into host cells (Figure).4 The coxsackie–adenoviral receptor molecule is a critical tight-junction protein important for cell–cell communication and for maintenance of cell membrane integrity. Interestingly, viruses such as CVB must use host signaling mechanisms, including tyrosine kinases such as Abl, fyn, or p56lck, to rearrange host actin and cytoskeleton and thus gain entry into the host cell and release viral RNA into the cytoplasm.5,6Download figureDownload PowerPointThe signaling pathways that lead from coxsackieviral (CVB) infection to the disruption of the dystrophin–sarcoglycans complex and activation of innate immunity. The virus enters the myocyte through internalization of the coxsackie–adenoviral receptor (CAR) and its coreceptor, decay-accelerating factor (DAF). The tyrosine kinases associated with these receptors, such as Fyn and p56lck, can modify the host cytoskeleton to enhance viral entry. The internalized virus, in turn, produces protease 2A, which can cleave dystrophin that functionally connects the cell-surface sarcoglycan complex with extracellular lamin and intracellular actin. This cleavage leads to host cytoskeleton remodeling and dilated cardiomyopathy. Viral proliferation and host cell remodeling is counterbalanced by innate immunity, activated by the toll-like receptors (TLR), whose signaling through MyD88/IRAK-4 can produce type I interferons (IFN) to attenuate the virus and can produce cytokines such as interleukin-6, engaging the gp130 receptor. The latter can stabilize the dystrophin complex and counteract the protease 2A effect, but this can be negated by the presence of suppressors of cytokine signaling (SOCS)-3. Paradoxically, innate immunity can also upregulate the viral CAR receptor, and, when sustained, it can lead to activation of acquired immunity and mobilization of T-cells into the infected myocardium. IRAK indicates interleukin-1 receptor associated kinase; IRF, interferon regulatory factor; MyD88, myeloid differentiation factor-88; and NF-κB, nuclear factor-κB.To facilitate entry into cells, it is not surprising that CVBs also produce proteases that can lyse the cell–cell or cell–matrix connections. CVB3 produces protease 2A, a cysteine endopeptidase that can specifically cleave the dystrophin–sarcoglycans complex, which is responsible for the linkage of myocyte cytoskeleton to the extracellular matrix.7 This cleavage leads to dystrophin dysfunction and to loss of sarcolemmal integrity, likely aiding viral entry. This action resembles that of the naturally occurring human mutations in the dystrophin–glycoprotein complex such as X-linked muscular dystrophies, which are often associated with dilated cardiomyopathy.8Following up on initial in vitro observations, in this issue of the Circulation, Xiong et al9 have gone on to show that the conditional expression of this protein is alone sufficient to lead to dilated cardiomyopathy in vivo. The presence of protease 2A coincided with the compromise of sarcolemmal integrity and the loss of intact dystrophin by immunostaining. These findings suggest that viral endopeptidases, when present in adequate concentrations or expressed for a sufficient duration, can produce myocyte cytoskeletal and sarcolemmal disruptions, leading to dilated cardiomyopathy. These findings indirectly show that the naturally occurring mutations, as seen in the X-linked dystrophies at the sarcoglycans complex, are critically related to the phenotype of cardiomyopathy. The viral myocarditis model, therefore, is a mimic of the genetically induced cardiomyopathy, disrupting the same cytoskeletal target in an acquired manner.8The advantage of the conditional heart-targeted model used by Xiong et al9 is that the protein is only expressed in the heart, and the transgene is only produced when the mice are adults. This strategy avoids the complications of having a protease 2A presence in utero, which can lead to unintended effects during development. On the other hand, the transgenic model forces the protease to be produced in relatively high quantities for a prolonged period, which probably does not occur with a natural viral infection. In the latter setting, the protease likely will be produced only for a brief few days when the virus is actively proliferating. Nevertheless, this study provides significant proof that the production of this cytoskeletal-modifying protease is sufficient to produce dilated cardiomyopathy.What role does the host immune response play in this setting? How does the host deal with the presence of foreign viral particles in the heart and elsewhere and successfully clear the viruses from the heart in the majority of the cases? On the other hand, how do we reconcile the presence of the inflammatory cell infiltrates that are seen on many biopsy sections and that can ultimately contribute to the evolution of dilated cardiomyopathy?The original Dallas criteria for the diagnosis of myocarditis on myocardial biopsies stipulated the presence of lymphocytic infiltrates concurrent with evidence of myocyte necrosis. Most experts would agree that in real practice, the Dallas criteria are overly strict, leading to underdiagnosis of the condition. Nevertheless, these criteria underscore that the host inflammatory response is an integral part of the disease process—but how does the viral infection lead to mobilization of lymphocytes to the myocardium?The presence of viruses or other foreign particles can trigger the activation of innate immune responses in the host tissue through a family of toll-like receptors. In contrast to the T- and B-cells of acquired immunity, which require perfect matching of specific antigenic peptide sequences for activation, the toll-like receptors require only very general triggers or pathogen-associated molecular patterns. Engagement of the toll-like receptors produces rapid signal transduction in the host, leading to activation of adaptor proteins such as MyD88, IRAK-4, and TRAF-6.10 This activation triggers translocation of interferon regulator factor transcription factors to the nucleus to produce interferons, and this activation also triggers translocation of nuclear factor-κB to produce cytokines. We have shown previously that excessive activation of the MyD-88/nuclear factor-κB axis leads to increased inflammation and higher mortality rates,11 whereas activation of interferon regulator factor-3 and interferons are protective and antiinflammatory for the host, with a reduced mortality rate.12In addition to the toll-like receptor family, there are other means by which the host cells, and particularly myocytes, can direct innate immunity to enhance host survival, attenuate the virus, or both. In addition to these positive regulators of host-defense responses outlined above, there are also systems of negative modulators that will counteract the cytokine activation. One system is the intracellular suppressors of cytokine signaling (SOCS) system of signaling pathways that negatively regulate innate immune response.13 The SOCS system particularly downregulates cytokine signals going through the gp130 receptor on the myocytes. The gp130 receptor engages cytokine ligands such as interleukin-6 and cardiotropin-1, which are cardiac myocyte growth and survival factors. Deficiency of gp130 signaling leads to increased apoptosis and susceptibility to other insults and injury such as ischemia or viral infection.Yajima et al14 have previously found that SOCS1 and SOCS3 signaling can downregulate the JAK/STAT signal-transduction pathways and significantly increase the host's susceptibility to CVB infection, but SOCS2 did not. However, SOCS1 also interferes with interferon signaling, making it difficult to dissociate the interferon-dependent and -independent contributions on host susceptibility. On the other hand, SOCS3 downregulates the JAK/STAT pathway but does not alter interferon signaling. SOCS3 transgenic mice-induced loss of STAT3 led to increased susceptibility to viral injury. This effect is mimicked by ablation of gp130-receptor signaling.13 The gp130-mediated protective effect seems to be mediated by STAT3 phosphorylation, leading intriguingly to a more robust dystrophin–sarcoglycan complex in the membrane, increasing the sarcolemmal integrity. This is compatible with the overall concept that viral infections engage host growth and replication machinery but also disrupt the membrane apparatus to gain efficient access to the intracellular compartment. If the cytoskeleton is maintained intact and the membrane remains robust, the viral infection is more attenuated, and the host survives better. The converse has been observed in dystrophin-deficient mdx mice, which have increased susceptibility to viral infection.15What are the implications of these findings for the clinician? First, viral infection can directly remodel the myocardium, leading to dilated cardiomyopathy. One example, discussed here, is that the production of viral protease 2A by CVB can directly cleave the dystrophin–sarcoglycans complex, leading to sarcolemmal disruption and dilated cardiomyopathy. On the other hand, the virus can also trigger innate immunity, which can strengthen the host to fight against the infection—for example, through activation of STAT3 and gp130 signaling for survival, and interferon regulator factor-3 triggering interferon production for systemic clearance of the virus. Unfortunately, activation of innate immunity can also have the adverse consequences of production of cytokines and costimulation of T-cells, leading to clonal expansion and inflammatory infiltrate. Excessive inflammation leads to paradoxical destruction of the host myocardium, leaving the patient worse off than he or she would have been with no inflammation at all.In a perfect world, one would like to see a host capable of recognizing the viral presence at the earliest opportunity and clearing the virus before it could have the chance to proliferate, elaborating proteases, and remodeling the matrix–cytoskeleton connections in the heart. The most effective approaches to date are either vaccination to induce immunologic memory or the administration of type I interferons to enhance viral clearance.16 Results of ongoing clinical trials evaluating the potential of interferons in rapidly mediating viral clearance and, possibly, improving clinical outcome, are eagerly anticipated. However, other intriguing treatment targets may also be important, including a means to inhibit SOCS3 or promote STAT3 signaling to strengthen the host; such a means could be useful for broad cases of cardiac injury. In addition, the ability to inhibit dystrophin–sarcoglycans breakdown, possibly through blockers of peptidases such as protease 2A, may also prevent cardiomyopathy of diverse origin.Ultimately, nature may produce the best tools to understand many of our biological enigmas. Indeed, viruses may be the best-designed nanoparticles for unraveling the mysteries of dilated cardiomyopathy, offering novel avenues for treatment of this most challenging condition.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Sources of FundingThis work was supported in part by grants from the Heart and Stroke Foundation (HSF) of Ontario, the Canadian Institutes of Health Research (CIHR), and the CHFNET and TACTICS Partnership Programs of the HSF and CIHR.DisclosuresNone.FootnotesCorrespondence to Peter Liu, MD, Institute of Circulatory and Respiratory Health, CIHR, NCSB 11–1266, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario, M5G 2C4, Canada. E-mail [email protected] References 1 Liu P, Mason J. Advances in the understanding of myocarditis. Circulation. 2001; 104: 1076–1082.CrossrefMedlineGoogle Scholar2 Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006; 113: 876–890.LinkGoogle Scholar3 Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005; 111: 887–893.LinkGoogle Scholar4 Martino T, Petric M, Weingartl H, Bergelson JM, Opavsky MA, Richardson CD, Modlin JF, Finberg RW, Kain K, Willis N, Gauntt CJ, Liu PP. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all 6 serotypes of coxsackievirus group B, and by swine vescicular disease virus. J Virol. 2000; 271: 99–108.CrossrefGoogle Scholar5 Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006; 124: 119–131.CrossrefMedlineGoogle Scholar6 Liu P, Aitken K, Kong YY, Martino T, Dawood F, Wen WH, Opavsky MA, Kozieradzki I, Bachmaier K, Straus D, Mak T, Penninger J. Essential role for the tyrosine kinase p56lck in coxsackievirus B3 mediated heart disease. Nat Med. 2000; 6: 429–434.CrossrefMedlineGoogle Scholar7 Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999; 5: 320–326.CrossrefMedlineGoogle Scholar8 Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, Neish SR, Smith EO, Towbin JA. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005; 112: 2799–2804.LinkGoogle Scholar9 Xiong D, Yajima T, Lim B-K, Stenbit A, Dublin A, Dalton N, Summers-Torres D, Molkentin JD, Duplain H, Wessely R, Chen J, Knowlton KU. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007: 115: 94–102.LinkGoogle Scholar10 Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006; 7: 131–137.CrossrefMedlineGoogle Scholar11 Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M, Yeh WC, Akira S, Liu PP. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of coxsackievirus B3 induced myocarditis, and influences type I interferon production. Circulation. 2005; 112: 2276–2285.LinkGoogle Scholar12 Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN. Protective role for interferon-beta in coxsackievirus B3 infection. Circulation. 2004; 110: 3540–3543.LinkGoogle Scholar13 Yajima T, Yasukawa H, Jeon ES, Xiong D, Dorner A, Iwatate M, Nara M, Zhou H, Summers-Torres D, Hoshijima M, Chien KR, Yoshimura A, Knowlton KU. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation. 2006; 114: 2364–2373.LinkGoogle Scholar14 Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M, Weitzman MD, Nakamura T, Woodard S, Xiong D, Yoshimura A, Chien KR, Knowlton KU. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Invest. 2003; 111: 469–478.CrossrefMedlineGoogle Scholar15 Xiong D, Lee GH, Badorff C, Dorner A, Lee S, Wolf P, Knowlton KU. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002; 8: 872–877.CrossrefMedlineGoogle Scholar16 Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003; 107: 2793–2798.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bironaitė D, Kažukauskienė I, Bogomolovas J, Daunoravičius D, Jakubauskas A, Vitkus D, Žurauskas E, Ručinskas K, Labeit S and Grabauskiene V (2022) Molecular Mechanisms behind Persistent Presence of Parvovirus B19 in Human Dilated Myocardium Cell Biology and Translational Medicine, Volume 15, 10.1007/5584_2021_702, (181-202), . Rroku A, Kottwitz J and Heidecker B (2020) Update on myocarditis – what we know so far and where we may be heading, European Heart Journal. Acute Cardiovascular Care, 10.1177/2048872620910109, 10:4, (455-467), Online publication date: 25-May-2021. Tabassum T, Rahman A, Araf Y, Ullah M and Hosen M (2021) Prospective selected biomarkers in COVID-19 diagnosis and treatment, Biomarkers in Medicine, 10.2217/bmm-2021-0038, 15:15, (1435-1449), Online publication date: 1-Oct-2021. Sharma V, Perry D and Eghtesady P (2020) Role of coxsackie‐adenovirus receptor in cardiac development and pathogenesis of congenital heart disease, Birth Defects Research, 10.1002/bdr2.1860, 113:7, (535-545), Online publication date: 15-Apr-2021. Tersalvi G, Vicenzi M, Calabretta D, Biasco L, Pedrazzini G and Winterton D (2020) Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms, Journal of Cardiac Failure, 10.1016/j.cardfail.2020.04.009, 26:6, (470-475), Online publication date: 1-Jun-2020. Crişan S, Tint D and Petrescu L (2019) Therapeutic Advances in Emergency Cardiology: A Focus on Acute Myocarditis, American Journal of Therapeutics, 10.1097/MJT.0000000000000921, 26:2, (e294-e300), Online publication date: 1-Mar-2019. Schultheiss H, Fairweather D, Caforio A, Escher F, Hershberger R, Lipshultz S, Liu P, Matsumori A, Mazzanti A, McMurray J and Priori S (2019) Dilated cardiomyopathy, Nature Reviews Disease Primers, 10.1038/s41572-019-0084-1, 5:1, Online publication date: 1-Dec-2019. Shaheen M, El-hadedy D and Ali Z (2019) Medical and Microbial Applications of Controlled Shape of Silver Nanoparticles Prepared by Ionizing Radiation, BioNanoScience, 10.1007/s12668-019-00622-2, 9:2, (414-422), Online publication date: 1-Jun-2019. Zeisel M, Dhawan P and Baumert T (2018) Tight junction proteins in gastrointestinal and liver disease, Gut, 10.1136/gutjnl-2018-316906, 68:3, (547-561), Online publication date: 1-Mar-2019. Hosseini S, Mirhosseini S, Taghian M, Salehi M, Farahani M, Bakhtiari F, Ghasemi-Pirbaluti M and Motaghi E (2018) First evidence of the presence of adenovirus type 8 in myocardium of patients with severe idiopathic dilated cardiomyopathy, Archives of Virology, 10.1007/s00705-018-3942-3, 163:10, (2895-2897), Online publication date: 1-Oct-2018. Zhao L and Fu Z (2018) Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy, Journal of Immunology Research, 10.1155/2018/5301548, 2018, (1-12), . Lee T, Hsu D, Kantor P, Towbin J, Ware S, Colan S, Chung W, Jefferies J, Rossano J, Castleberry C, Addonizio L, Lal A, Lamour J, Miller E, Thrush P, Czachor J, Razoky H, Hill A and Lipshultz S (2017) Pediatric Cardiomyopathies, Circulation Research, 121:7, (855-873), Online publication date: 15-Sep-2017. Gil K, Pawlak A, Gil R, Frontczak-Baniewicz M and Bil J (2016) The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review, Advances in Medical Sciences, 10.1016/j.advms.2016.07.001, 61:2, (331-343), Online publication date: 1-Sep-2016. Gaaloul I, Riabi S, Evans M, Hunter T, Huber S and Aouni M (2016) Coxsackievirus B heart infections and their putative contribution to sudden unexpected death: An 8-year review of patients and victims in the coastal region of Tunisia, Forensic Science International, 10.1016/j.forsciint.2016.09.014, 268, (73-80), Online publication date: 1-Nov-2016. ZHANG T, MIAO W, WANG S, WEI M, SU G and LI Z (2015)(2015) Acute myocarditis mimicking ST-elevation myocardial infarction: A case report and review of the literature, Experimental and Therapeutic Medicine, 10.3892/etm.2015.2576, 10:2, (459-464), Online publication date: 1-Aug-2015. GAALOUL I, RIABI S, HARRATH R, HUNTER T, HAMDA K, GHZALA A, HUBER S and AOUNI M (2014)(2014) Coxsackievirus B detection in cases of myocarditis, myopericarditis, pericarditis and dilated cardiomyopathy in hospitalized patients, Molecular Medicine Reports, 10.3892/mmr.2014.2578, 10:6, (2811-2818), Online publication date: 1-Dec-2014. Valaperti A, Nishii M, Liu Y, Yang H, Naito K, Liu P and Eriksson U (2014) The adapter protein c-Cbl-associated protein (CAP) protects from acute CVB3-mediated myocarditis through stabilization of type I interferon production and reduced cytotoxicity, Basic Research in Cardiology, 10.1007/s00395-014-0411-3, 109:3, Online publication date: 1-May-2014. Hu Y, Dong C, Yue Y and Xiong S (2014) In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells, Archives of Virology, 10.1007/s00705-014-2098-z, 159:9, (2411-2419), Online publication date: 1-Sep-2014. Pankuweit S and Klingel K (2012) Viral myocarditis: from experimental models to molecular diagnosis in patients, Heart Failure Reviews, 10.1007/s10741-012-9357-4, 18:6, (683-702), Online publication date: 1-Nov-2013. Caforio A, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix S, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto Y, Ristic A, Schultheiss H, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P and Elliott P (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, European Heart Journal, 10.1093/eurheartj/eht210, 34:33, (2636-2648), Online publication date: 1-Sep-2013. Dandel M, Wallukat G, Englert A and Hetzer R (2013) Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension, Atherosclerosis Supplements, 10.1016/j.atherosclerosissup.2012.10.029, 14:1, (203-211), Online publication date: 1-Jan-2013. Maisch B and Pankuweit S (2012) Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives, Heart Failure Reviews, 10.1007/s10741-012-9362-7, 18:6, (761-795), Online publication date: 1-Nov-2013. Pankuweit S and Maisch B (2013) Ätiologie, Diagnose, Management und Therapie der MyokarditisEtiology, diagnosis, management, and treatment of myocarditis, Herz, 10.1007/s00059-013-3988-7, 38:8, (855-861), Online publication date: 1-Dec-2013. Maisch B and Pankuweit S (2012) Current treatment options in (peri)myocarditis and inflammatory cardiomyopathyAktuelle Behandlungsoptionen bei (Peri-)Myokarditis und inflammatorischer Kardiomyopathie, Herz, 10.1007/s00059-012-3679-9, 37:6, (644-656), Online publication date: 1-Sep-2012. Sagar S, Liu P and Cooper L (2012) Myocarditis, The Lancet, 10.1016/S0140-6736(11)60648-X, 379:9817, (738-747), Online publication date: 1-Feb-2012. (2012) Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie Klinische Immunologie, 10.1016/B978-3-437-23256-5.16001-1, (e1-e80), . Liu P and Baughman K (2012) Myocarditis Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10.1016/B978-1-4377-0398-6.00070-6, (1595-1610), . Piran S, Liu P, Morales A and Hershberger R (2012) Where Genome Meets Phenome: Rationale for Integrating Genetic and Protein Biomarkers in the Diagnosis and Management of Dilated Cardiomyopathy and Heart Failure, Journal of the American College of Cardiology, 10.1016/j.jacc.2012.05.005, 60:4, (283-289), Online publication date: 1-Jul-2012. Yusuf S, Sharma J, Durand J and Banchs J (2014) Endocarditis and myocarditis: a brief review, Expert Review of Cardiovascular Therapy, 10.1586/erc.12.107, 10:9, (1153-1164), Online publication date: 1-Sep-2012. Dandel M, Wallukat G, Potapov E and Hetzer R (2012) Role of β1-adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy, Immunobiology, 10.1016/j.imbio.2011.07.012, 217:5, (511-520), Online publication date: 1-May-2012. Tátrai E, Hartyánszky I, Lászik A, Acsády G, Sótonyi P and Hubay M (2010) The Role of Viral Infections in the Development of Dilated Cardiomyopathy, Pathology & Oncology Research, 10.1007/s12253-010-9302-6, 17:2, (229-235), Online publication date: 1-Jun-2011. Weerakoon K, Kularatne S, Edussuriya D, Kodikara S, Gunatilake L, Pinto V, Seneviratne A and Gunasena S (2011) Histopathological diagnosis of myocarditis in a dengue outbreak in Sri Lanka, 2009, BMC Research Notes, 10.1186/1756-0500-4-268, 4:1, Online publication date: 1-Dec-2011. Foerster S, Canter C, Cinar A, Sleeper L, Webber S, Pahl E, Kantor P, Alvarez J, Colan S, Jefferies J, Lamour J, Margossian R, Messere J, Rusconi P, Shaddy R, Towbin J, Wilkinson J and Lipshultz S (2010) Ventricular Remodeling and Survival Are More Favorable for Myocarditis Than For Idiopathic Dilated Cardiomyopathy in Childhood, Circulation: Heart Failure, 3:6, (689-697), Online publication date: 1-Nov-2010. Jahns R, Boivin V, Ertl G and Lohse M (2010) Pathogenic relevance of autoantibodies in dilated cardiomyopathy Inflammatory Cardiomyopathy (DCMi), 10.1007/978-3-7643-8352-7_7, (157-170), . Pankuweit S and Maisch B (2010) Das Herz bei viralen InfektionenThe heart in viral infections, Der Internist, 10.1007/s00108-009-2559-8, 51:7, (836-843), Online publication date: 1-Jul-2010. Poller W, Hajjar R, Schultheiss H and Fechner H (2010) Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure, Cardiovascular Research, 10.1093/cvr/cvq056, 86:3, (353-364), Online publication date: 1-Jun-2010. Ruppert V, Meyer T, Struwe C, Petersen J, Perrot A, Posch M, Özcelik C, Richter A, Maisch B and Pankuweit S (2010) Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy, European Journal of Human Genetics, 10.1038/ejhg.2010.3, 18:6, (694-699), Online publication date: 1-Jun-2010. Heusch P, Aker S, Boengler K, Deindl E, van de Sand A, Klein K, Rassaf T, Konietzka I, Sewell A, Menazza S, Canton M, Heusch G, Di Lisa F and Schulz R (2010) Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S -nitrosylation , American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.01034.2009, 299:2, (H446-H453), Online publication date: 1-Aug-2010. Pankuweit S, Richter A, Ruppert V and Maisch B (2009) Familiäre Prädisposition und mikrobielle Ätiologie bei dilatativer KardiomyopathieFamilial Predisposition and Microbial Etiology in Dilated Cardiomyopathy, Herz Kardiovaskuläre Erkrankungen, 10.1007/s00059-009-3200-2, 34:2, (110-116), Online publication date: 1-Mar-2009. Heymans S, Hirsch E, Anker S, Aukrust P, Balligand J, Cohen-Tervaert J, Drexler H, Filippatos G, Felix S, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus W, Pieske B, Ponikowski P, Schroen B, Schultheiss H, Tschöpe C, van Bilsen M, Zannad F, McMurray J and Shah A (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology, European Journal of Heart Failure, 10.1093/eurjhf/hfn043, 11:2, (119-129), Online publication date: 1-Feb-2009. Rose N (2009) Myocarditis: Infection Versus Autoimmunity, Journal of Clinical Immunology, 10.1007/s10875-009-9339-z, 29:6, (730-737), Online publication date: 1-Nov-2009. Pankuweit S, Ruppert V, Maisch B and Meyer T Toll-Like Receptors: Potential Targets for Therapeutic Interventions Fundamentals of Tissue Engineering and Regenerative Medicine, 10.1007/978-3-540-77755-7_51, (749-755) Caforio A and Iliceto S (2008) Genetically determined myocarditis: clinical presentation and immunological characteristics, Current Opinion in Cardiology, 10.1097/HCO.0b013e3282fbf572, 23:3, (219-226), Online publication date: 1-May-2008. Levin M and Hoebeke J (2009) Cross-talk between anti-β 1 -adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease , Autoimmunity, 10.1080/08916930802031702, 41:6, (429-433), Online publication date: 1-Jan-2008. Caforio A, Vinci A and Iliceto S (2009) Anti-heart autoantibodies in familial dilated cardiomyopathy, Autoimmunity, 10.1080/08916930802031546, 41:6, (462-469), Online publication date: 1-Jan-2008. Yu K, Zhou L, Wang Y, Yu C, Wang Z, Liu H, Wei H, Han L, Cheng J, Wang F, Wang D and Zhao C (2022) Mechanisms and Therapeutic Strategies of Viral Myocarditis Targeting Autophagy, Frontiers in Pharmacology, 10.3389/fphar.2022.843103, 13 Favere K, Bosman M, Klingel K, Heymans S, Van Linthout S, Delputte P, De Sutter J, Heidbuchel H and Guns P (2021) Toll-Like Receptors: Are They Taking a Toll on the Heart in Viral Myocarditis?, Viruses, 10.3390/v13061003, 13:6, (1003) Liu C, Liu J, Wu D, Luo S, Li W, Chen L, Liu Z and Yu B (2022) Construction of Immune-Related ceRNA Network in Dilated Cardiomyopathy: Based on Sex Differences, Frontiers in Genetics, 10.3389/fgene.2022.882324, 13 Yue Y, Gui J, Ai W, Xu W, Xiong S and Gaetano C (2011) Direct Gene Transfer with IP-10 Mutant Ameliorates Mouse CVB3-Induced Myocarditis by Blunting Th1 Immune Responses, PLoS ONE, 10.1371/journal.pone.0018186, 6:3, (e18186) Dennert R, Crijns H and Heymans S (2008) Acute viral myocarditis, European Heart Journal, 10.1093/eurheartj/ehn296, 29:17, (2073-2082) Zhang Y, Jiang L, Zhang M and Lv K (2014) Galectin-9 Induced Myeloid Suppressor Cells Expand Regulatory T Cells in an IL-10-Dependent Manner in CVB3-Induced Acute Myocarditis, International Journal of Molecular Sciences, 10.3390/ijms15033356, 15:3, (3356-3372) January 2, 2007Vol 115, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.106.670554PMID: 17200452 Originally publishedJanuary 2, 2007 Keywordscardiomyopathymyocarditisimmune systemheart failureEditorialsinflammationPDF download Advertisement SubjectsAnimal Models of Human DiseaseHeart FailureMyocardial Biology
Publication Year: 2007
Publication Date: 2007-01-02
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 74
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot